Feed HLNCF
HL
Haleon plc HLNCF · OTC
$4.15 -1.89% (-$0.08)
Depth
- Market cap
- £27.8B
- Enterprise value
- £35.1B
- P/E
- 18.3x
- Forward P/E
- 14.5x
- PEG
- 1.1x
- P/S
- 2.5x
- P/FCF
- 12.0x
- EV/EBITDA
- 13.5x
- ROIC
- 6.1%
- Gross margin
- 61.8%
- Net margin
- 13.8%
- Dividend yield
- 3.12%
- Payout ratio
- 56.9%
- Net debt/EBITDA
- 2.8x
- Beta
- 0.24
- Free float
- 95.5%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Brian James McNamara
Employees
24,561
Headquarters
Weybridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 20% a year over the last 3 years.
- What to watch: Revenue grew by only 0.5% a year over the last 3 years.
- What to watch: It missed profit estimates 5 times in the last 8 quarters.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 GBP of revenue, 14 GBP is left as net profit.
- What to watch: It earns only 6.1 GBP a year on every 100 GBP of invested capital.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number